Search Results - "Rubant, S."

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up by Papp, K.A., Lebwohl, M.G., Puig, L., Ohtsuki, M., Beissert, S., Zeng, J., Rubant, S., Sinvhal, R., Zhao, Y., Soliman, A.M., Alperovich, G., Leonardi, C.

“…Summary Background Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long‐term evaluation to…”
Get full text

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial by Thaçi, D., Eyerich, K., Pinter, A., Sebastian, M., Unnebrink, K., Rubant, S., Williams, D. A., Weisenseel, P.

“…Summary Background Fumaric acid esters (FAEs; Fumaderm®) are the most frequently prescribed first‐line systemic treatment for moderate‐to‐severe plaque…”
Get full text

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study by Thaçi, D., Papp, K., Marcoux, D., Weibel, L., Pinter, A., Ghislain, P.‐D., Landells, I., Hoeger, P.H., Unnebrink, K., Seyger, M.M.B., Williams, D.A., Rubant, S., Philipp, S.

“…Summary Background Adalimumab (ADA) (Humira®, AbbVie Inc., U.S.A.) is approved by the European Medicines Agency for children aged ≥ 4 years with severe plaque…”
Get full text

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial by Thaçi, D., Soliman, A.M., Eyerich, K., Pinter, A., Sebastian, M., Unnebrink, K., Rubant, S., Williams, D.A., Weisenseel, P.

“…Background In a phase 3 clinical study, patients from Germany with moderate to severe psoriasis who were naïve to systemic treatment and received risankizumab…”
Get full text

Productive Infection of Human Primary Cells and Cell Lines with Porcine Endogenous Retroviruses by Specke, V., Rubant, S., Denner, J.

“…Porcine endogenous retroviruses (PERVs) infect human cells in vitro and therefore represent a risk for xenotransplantation. However, first clinical…”
Get full text

Constitutive and functionally relevant expression of JAM-C on platelets by Erpenbeck, Luise, Rubant, Simone, Hardt, Katja, Santoso, Sentot, Boehncke, Wolf-Henning, Schön, Michael P, Ludwig, Ralf J

Get more information